SCHEMBL14474660

SCHEMBL14474660

CCNc1nc(-c2cccnc2)nc2c(OC)cc(-c3cc(F)ccc3F)cc12

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP1A2 P05177 5/20 0.46
▸ CYP3A4 P08684 5/20 0.46
▸ TSHR P16473 4/20 0.46
▸ CYP2C19 P33261 4/20 0.46
▸ HSD17B10 Q99714 4/20 0.46
▸ USP2 O75604 3/20 0.46
▸ CYP2D6 P10635 3/20 0.46
▸ LMNA P02545 3/20 0.46
▸ CYP2C9 P11712 2/20 0.46
▸ CLK4 Q9HAZ1 2/20 0.46
▸ ALDH1A1 P00352 2/20 0.46
▸ ALOX15 P16050 2/20 0.46
▸ MAPK1 P28482 2/20 0.46
▸ MEN1 O00255 1/20 0.46
▸ TP53 P04637 1/20 0.46
▸ KMT2A Q03164 1/20 0.46
▸ PDE5A O76074 4/20 0.46
▸ USP1 O94782 1/20 0.43
▸ WDR48 Q8TAF3 1/20 0.43
▸ POLB P06746 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16184625 0.93 USP2 (0.45) CYP1A2CYP3A4TSHRCYP2C19HSD17B10
SCHEMBL14474236 0.93 CYP1A2 (0.46) CYP1A2CYP3A4TSHRCYP2C19HSD17B10
SCHEMBL16184624 0.91 GBA1 (0.48) CYP1A2CYP3A4TSHRCYP2C19HSD17B10
SCHEMBL16184614 0.91 USP2 (0.45) CYP1A2CYP3A4TSHRCYP2C19HSD17B10
SCHEMBL16184471 0.91 USP2 (0.48) CYP1A2CYP3A4TSHRCYP2C19HSD17B10
SCHEMBL16184621 0.90 CYP1A2 (0.44) CYP1A2CYP3A4TSHRCYP2C19HSD17B10
SCHEMBL16184617 0.90 LMNA (0.49) CYP1A2CYP3A4TSHRCYP2C19HSD17B10
SCHEMBL16184623 0.90 USP2 (0.44) CYP1A2CYP3A4TSHRCYP2C19HSD17B10
SCHEMBL16184615 0.90 CYP1A2 (0.44) CYP1A2CYP3A4TSHRCYP2C19HSD17B10
SCHEMBL14475986 0.90 CYP1A2 (0.46) CYP1A2CYP3A4TSHRCYP2C19HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140315886-A1 QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2014-10-23 — — US disclosed
US-20140315886-A1 QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2014-10-23 — — US disclosed
WO-2013003586-A1 QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-01-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140315886-A1 QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE PPP2CA, PPP4C, PPP3CB CYP1A2 2971/4885CYP3A4 4456/4885TSHR 2280/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback